Patient Monitoring and Follow-Up Protocol for Cannabis Prescribers

Why Structured Follow-Up Is Non-Negotiable in Cannabis Prescribing

• Cannabis is a Schedule 2 controlled drug — prescribers carry enhanced duty of care compared to standard medications
• Patient responses to cannabis are highly individual and cannot be fully predicted at initiation
• Dose titration, product changes, and safety monitoring all require regular structured review
• Professional indemnity and CQC compliance both depend on documented follow-up activity

The prescribing of cannabis-based medicines does not end at the consultation and the issuing of a prescription. It requires a commitment to ongoing patient monitoring that is proportionate to the risk profile of the medication and the vulnerability of the patient. Clinicians who prescribe cannabis without a structured follow-up framework are not meeting the standard of care expected by the GMC or the specialist medical community.

Recommended Follow-Up Schedule

• Week 2 post-initiation: early tolerability check, titration review, address any acute adverse events
• Month 1: formal outcome assessment using validated tools (NRS, GAD-7, PHQ-9, PSQI for sleep)
• Month 3: comprehensive review — therapeutic benefit, dosing stability, risk factors, any concerning trends
• Month 6 and annually: full re-assessment of clinical need, risk-benefit ratio, and continued prescription justification

The early follow-up appointments at 2 weeks and 1 month are clinically critical. Most adverse events and titration failures occur in the first 4 weeks of cannabis prescribing. Patients who have not yet found their therapeutic dose need more intensive support than those who are established on a stable regimen. Telephone or video consultations are appropriate for early follow-up and improve access and adherence.

Validated Outcome Measures for Cannabis Prescribing

• Numeric Rating Scale (NRS) or Brief Pain Inventory (BPI) for pain conditions
• Generalised Anxiety Disorder-7 (GAD-7) for anxiety presentations
• Patient Health Questionnaire-9 (PHQ-9) for depression and mood monitoring
• Pittsburgh Sleep Quality Index (PSQI) for sleep-related indications

The use of validated, standardised outcome measures transforms cannabis monitoring from a subjective conversation into a quantifiable record of therapeutic effect. These data serve multiple purposes: they guide clinical decisions, they support reimbursement discussions, and they contribute to the real-world evidence base that will inform future NICE guideline updates. Prescribers who collect outcome data systematically are contributing to the professionalisation of cannabis medicine in the UK.

Red Flags Requiring Urgent Review or Discontinuation

• New or worsening psychotic symptoms: immediate psychiatric referral and cannabis discontinuation
• Cardiovascular events: chest pain, palpitations, or syncope warrant urgent medical assessment
• Dependence indicators: dose escalation without clinical justification, loss of control, withdrawal symptoms
• Domestic or safeguarding concerns arising from cannabis use within the patient’s household

Prescribers must have a clear protocol for escalation when red flags are identified. This includes the ability to conduct an emergency telephone review, to refer urgently to mental health services, and to discontinue prescribing where patient safety is at risk. The prescribing record must document any decision to discontinue or escalate, with clear clinical reasoning. A graduated withdrawal plan should be offered to patients where dependency has developed.